Lam Capital Joins Funding Round Alongside Foxconn, Pegatron, and Wistron
TAIPEI, Aug. 2, 2025 /PRNewswire/ -- Zettabyte, a fast-growing innovator in AI data center infrastructure...
Lam Capital Joins Funding Round Alongside Foxconn, Pegatron, and Wistron
TAIPEI, Aug. 2, 2025 /PRNewswire/ -- Zettabyte, a fast-growing innovator in AI data center infrastructure...
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
VANCOUVER, BC, Aug. 1, 2025 /CNW/ - SKRR Exploration Inc. (TSXV: SKRR) (FSE:...
Award-Winning Global Entertainment Company Sets Sail for Dynamic New Chapter of Success
TORONTO, Aug. 1, 2025 /PRNewswire/ -- Boat Rocker Studios, the dynamic, award-winning global entertainment...
Award-Winning Global Entertainment Company Sets Sail for Dynamic New Chapter of Success
TORONTO, Aug. 1, 2025 /CNW/ -- Boat Rocker Studios, the dynamic, award-winning global entertainment...
The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.
The partnership aims to expand access to fresh food and enhance health outcomes in rural southwest Michigan food deserts
DETROIT, July 31, 2025 /PRNewswire/ -- Meridian...
LONDON, July 31, 2025 /CNW/ - Canada Pension Plan Investment Board (CPP Investments) today announced that it has reached a definitive agreement to sell...
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm’s length note payable by the issuance of 3,209,523 units, at a price of $0.021 per unit, being the same issue price and security being offering pursuant to the private placement.
The mobile health clinic will begin service in August for the 2025-2026 school year
HILO, Hawai'i, July 30, 2025 /PRNewswire/ -- 'Ohana Health Plan,...
ATLANTA, July 30, 2025 /PRNewswire/ -- Peach State Health Plan ("PSHP"), a leading managed care organization in Georgia and a company of Centene Corporation...